Covance recognized for providing superior vaccine services to biopharmaceutical industry.
Princeton, NJ-May 5, 2008-Covance (www.covance.com), the world’s largest publicly traded contract research organization, today announced that it has won the “Best Contract Research Organization (CRO)” award at the 2008 World Vaccine Congress, held recently in Washington, DC. As part of the Vaccine Industry Excellence (ViE) awards, the Best CRO award is designed to highlight the importance of contract research services within the vaccine industry. This award recognizes Covance as best-in-class when it comes to providing services that support vaccine development.
“This recognition reaffirms our commitment to providing vaccine services that encompass all phases of development,” said Wendel Barr, chief operating officer for Covance. “We understand that each vaccine is unique, and therefore we offer services and experience-including scientific, technical, and regulatory expertise-across different types of vaccines to help guide our customers through the complexities of vaccine development.”
A panel of international judges selected Covance based on the company’s state-of-the-art facilities, vaccine services, and superior customer relations that together help biopharmaceutical companies speed vaccine development. The ViE Awards were created to honor and generate public recognition of the efforts, accomplishments, and positive contributions of organizations and individuals in the global vaccine industry.
The global vaccine market generated sales of $13.5 billion in 2006 and is expected to reach $24.8 billion by 2013, according to a 2007 report published by Wood Mackenzie, a research and consulting firm.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.